# Ryne Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ryne-biotechnology

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.ryne-bio.com
- Total disclosed funding: $3M
- Latest round: Seed (Jun 13, 2022)
- Investors on record: 1

## About

Based in California, US, Ryne Biotechnology Inc. operates as a biotechnology company specializing in neuron replacement therapies. In February 2023 the firm raised USD 4 million in grant funding from investor California Institute for Regenerative Medicine.

The company is working on the development of neuron replacement therapies as potential disease-modifying treatments for neurological disorders, by leveraging induced pluripotent stem cell (iPSC) technology. The company’s lead program is iPSC dopamine neuron progenitor (RNDP-001) for the treatment of inherited and idiopathic forms of Parkinson’s Disease. Other programs in Ryne’s pipeline are Gene-modified iPSC including RNDP-002 for mild to severe rapid progressing Parkinson’s disease, and  RNDP-003 for young onset Parkinson’s disease, in discovery and pre-clinical stages as of February 2023.

The company plans to utilize its February 2023 funding to accelerate its lead program RNDP-001, through the submission of an Investigational New Drug (IND) application.

## Funding rounds

- Seed, Jun 13, 2022, $3M — Saisei Ventures

## Investors

- Saisei Ventures (https://capitalatlas.ai/funds/saisei-ventures) — Seed